Drugs / OPL-CCL2-LPM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00856674 | Mar 2009 → Jun 2010 | IgA glomerulonephritis, proteinuria | Osprey Pharmaceuticals USA, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPL-CCL2-LPM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856674 ↗ |
| Action | Inhibit | “an enzyme that inhibits protein production by the leukocytes and prevents the leukocytes from migrating into the kidney” NCT00856674 ↗ |
| Modality | Protein / enzyme biologic | “CCL2-LPM is composed of the messenger chemokine, CCL2, fused to an enzyme” NCT00856674 ↗ |
| Route | Intravenous | “intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg” NCT00856674 ↗ |